Arkolith/Insider Trading/KROS/Form 4

Bienaime Jean Jacques

DirectorKeros Therapeutics, Inc. (KROS) · full profile →Form 4 · filed Jul 17, 2026
Net Buying
Open-Market Buys
$11K
Open-Market Sells
$0
Net Open-Market Flow
$11K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 15, 2026Buy(P)1K$10.61$11K19K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001221590-26-000023) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML